Seasonal trivalent influenza vaccine, Anflu® — Competitive Intelligence Brief

Seasonal trivalent influenza vaccine, Anflu® (Seasonal trivalent influenza vaccine, Anflu®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

marketed inactivated influenza vaccine Immunology Biologic

Target snapshot

Seasonal trivalent influenza vaccine, Anflu® (Seasonal trivalent influenza vaccine, Anflu®) — Center for Disease Prevention and Control of Beijing Military Region. The vaccine stimulates the immune system to produce antibodies and cellular immunity against three seasonal influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Seasonal trivalent influenza vaccine, Anflu® TARGET	Seasonal trivalent influenza vaccine, Anflu®	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
Trivalent split Inf	Trivalent split Inf	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Inactivated influenza vaccine
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine
trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class